The five-year deal governs user fees the industry pays the FDA to fund product reviews. Revenue including those fees is expected to total $1.9 billion, the report said, about double the current version’s amount.
The current agreement is set to expire in September.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
